Literature DB >> 3395358

Cefazolin serum protein binding and its inhibition by bilirubin, fatty acids and other drugs.

M O Decroix1, R Zini, J C Chaumeil, J P Tillement.   

Abstract

This paper describes the protein binding of cefazolin to human serum and to human serum albumin (HSA) using equilibrium dialysis. The drug is exclusively bound to HSA with a moderate affinity, Ka = 16,600 +/- 1600 M-1, and one saturable binding site, n = 0.73 +/- 0.02. Moreover cefazolin shows a dose-dependent binding leading a possible increase of the free fraction (when its total concentration increases). This antibiotic is displaced by free fatty acids (FFA) and bilirubin. Cefazolin binding to human serum and human serum albumin (HSA) was studied in presence of acidic drugs. At low concentrations clofibric acid and phenylbutazone both exhibiting high affinity for HSA displace strongly cefazolin. Valproic and salicylic acids, sulfamethoxazole, cefoperazone which have approximately the same affinity as cefazolin, must be used at higher concentrations to displace this antibiotic. A particular phenomenon was observed with cefazolin on HSA when associated with furosemide. A low concentration (5-25 microM) of this drug induces a positive cooperativity of binding between cefazolin and HSA. But at a molar ratio of furosemide to albumin greater than one, such cooperative interaction disappears and a competitive inhibition of cefazolin binding occurs. For all drugs studied, a competitive inhibition was found except for tryptophan. Finally, it is concluded that cefazolin shares the warfarin binding site on HSA.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3395358     DOI: 10.1016/0006-2952(88)90044-5

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  10 in total

1.  Protein binding of cefazolin is saturable in vivo both between and within patients.

Authors:  Jane W A Vella-Brincat; Evan J Begg; Carl M J Kirkpatrick; Mei Zhang; Stephen T Chambers; Kate Gallagher
Journal:  Br J Clin Pharmacol       Date:  2007-01-12       Impact factor: 4.335

Review 2.  Therapeutic drug monitoring in pregnancy: rationale and current status.

Authors:  C Knott; F Reynolds
Journal:  Clin Pharmacokinet       Date:  1990-12       Impact factor: 6.447

3.  Alterations in cefalosporin levels in the serum and mandible of hyperlipaedemic rats after co-administration of ibuprofen.

Authors:  E Tsivou; I Melakopoulos; A Kotsiou; S Anagnostopoulou; C Tesseromatis
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2005 Jul-Sep       Impact factor: 2.441

4.  Interactions of aldosterone antagonist diuretics with human serum proteins.

Authors:  N Takamura; T Maruyama; S Ahmed; A Suenaga; M Otagiri
Journal:  Pharm Res       Date:  1997-04       Impact factor: 4.200

5.  Interaction of antibiotics and warfarin in pediatric cardiology patients.

Authors:  M C Johnson; M Wood; V Vaughn; L Cowan; A M Sharkey
Journal:  Pediatr Cardiol       Date:  2005 Sep-Oct       Impact factor: 1.655

6.  Application of a Physiologically Based Pharmacokinetic Model to Predict Cefazolin and Cefuroxime Disposition in Obese Pregnant Women Undergoing Caesarean Section.

Authors:  Hanadi H Alrammaal; Khaled Abduljalil; Victoria Hodgetts Morton; R Katie Morris; John F Marriott; Hsu P Chong; Hannah K Batchelor
Journal:  Pharmaceutics       Date:  2022-05-30       Impact factor: 6.525

7.  Usefulness of competitive inhibitors of protein binding for improving the pharmacokinetics of 186Re-MAG3-conjugated bisphosphonate (186Re-MAG3-HBP), an agent for treatment of painful bone metastases.

Authors:  Kazuma Ogawa; Takahiro Mukai; Keiichi Kawai; Norito Takamura; Hirofumi Hanaoka; Kazuyuki Hashimoto; Kazuhiro Shiba; Hirofumi Mori; Hideo Saji
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-08-16       Impact factor: 9.236

8.  Cefazolin plasma protein binding and its covariates in neonates.

Authors:  A Smits; A Kulo; R Verbesselt; G Naulaers; J de Hoon; P Vermeersch; K Allegaert
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-07-26       Impact factor: 3.267

9.  Effects of cardiopulmonary bypass on the disposition of cefazolin in patients undergoing cardiothoracic surgery.

Authors:  Mizuho Asada; Masashi Nagata; Tomohiro Mizuno; Tokujiro Uchida; Naoki Kurashima; Hiromitsu Takahashi; Koshi Makita; Hirokuni Arai; Hirotoshi Echizen; Masato Yasuhara
Journal:  Pharmacol Res Perspect       Date:  2018-11-05

10.  Canine Albumin Polymorphisms and Their Impact on Drug Plasma Protein Binding.

Authors:  Ana P Costa; Michael H Court; Neal S Burke; Zhaohui Zhu; Katrina L Mealey; Nicolas F Villarino
Journal:  Drug Metab Dispos       Date:  2019-09-03       Impact factor: 3.922

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.